The gene therapy market is still in its infancy but poised for significant growth, with an approximate 25% increase in therapies in the pipeline as compared to 2018. However, the launch of a gene therapy is an event with limited case examples to follow and numerous unique considerations.
Precision’s David Carr and Jeremy Schafer identify three key considerations and critical steps to address them for manufacturers seeking to reduce product launch barriers in the gene therapy space.
Read the full article here!